Transdermal delivery of drugs has become the viable and successful dosage form due to its clinical benefits. It might be the most efficient, safest and convenient dosage form for drug delivery. In order to consider the feasibility of a number of cardiovascular drugs to transdermal delivery, a pharmacokinetic approach to predict plasma drug levels was applied. The kinetic and biological parameters, identified as important to transdermal delivery, of the drugs studied were either collected from literature or determined experimentally. The analysis demonstrated that the steady-state concentrations (Css) predicted by the kinetic model in mg/ml of propranolol, procainamide, verapamil, methyldopa, disopyramide and quinidine were 0.434, 5.999, 0.108, 2.322, 2.508 and 2.585, respectively. A linear relationship was found between the predicted and target Css (r = 0.974). In conclusion, the findings presented are promising for further in vitro and in vivo studies on the transdermal delivery of verapamil and seem to be a reasonable candidate. Increasing the surface area of the device for propranolol, procainamide, disopyramide and methyldopa will accelerate the attainment of effective plasma levels but will eventually lead to an acceptably large device. In addition, the including of penetration enhancer factor may clear the feasibility of the drugs studied and is highly recommended.